A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous (i.v.) Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids
Phase of Trial: Phase III
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Male osteoporosis; Osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 16 Oct 2017 Planned End Date changed from 16 Apr 2018 to 2 Mar 2018.
- 16 Oct 2017 Planned primary completion date changed from 16 Apr 2018 to 2 Mar 2018.
- 10 Jun 2017 Biomarkers information updated